Antineoplastic Combined Chemotherapy Protocols
Doxorubicin
Cyclophosphamide
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Osteosarcoma
Combined Modality Therapy
Cisplatin
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Disease-Free Survival
Treatment Outcome
Chemotherapy, Adjuvant
Prognosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Retrospective Studies
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Clinical Protocols
Antibiotics, Antineoplastic
Antineoplastic Agents, Phytogenic
Etoposide
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Neoplasms
Neoadjuvant Therapy
Antineoplastic Agents, Alkylating
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Drug Administration Schedule
Paclitaxel
Methotrexate
Survival Analysis
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Neoplasm Staging
Survival Rate
Drug Resistance, Neoplasm
Bleomycin
Taxoids
Ifosfamide
Cytarabine
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Organoplatinum Compounds
Induction Chemotherapy
Drug Screening Assays, Antitumor
Dose-Response Relationship, Drug
Neoplasm Recurrence, Local
Anthracyclines
Apoptosis
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Ovarian Neoplasms
Daunorubicin
Clinical Trials as Topic
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Neoplasm Metastasis
Carmustine
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Follow-Up Studies
Carcinoma, Non-Small-Cell Lung
Tumor Cells, Cultured
Nausea
Camptothecin
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Colorectal Neoplasms
Chemotherapy, Cancer, Regional Perfusion
Salvage Therapy
Cell Survival
Mitomycin
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Prospective Studies
Dacarbazine
Infusions, Intravenous
Melphalan
Transplantation, Autologous
Testicular Neoplasms
Radiotherapy, Adjuvant
Leukemia P388
Hodgkin Disease
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Xenograft Model Antitumor Assays
Drug Evaluation
Antibodies, Monoclonal, Humanized
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
6-Mercaptopurine
Gallium
Randomized Controlled Trials as Topic
Tumor Markers, Biological
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Carcinoma, Squamous Cell
Kaplan-Meier Estimate
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Neoplasms, Germ Cell and Embryonal
Carcinoma
Bryostatins
Ellipticines
Phospholipid Ethers
Phospholipids which have an alcohol moiety in ethereal linkage with a saturated or unsaturated aliphatic alcohol. They are usually derivatives of phosphoglycerols or phosphatidates. The other two alcohol groups of the glycerol backbone are usually in ester linkage. These compounds are widely distributed in animal tissues.
Granulocyte Colony-Stimulating Factor
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
Mice, Nude
Floxuridine
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Infusions, Intra-Arterial
Gloves, Protective
Coverings for the hands, usually with separations for the fingers, made of various materials, for protection against infections, toxic substances, extremes of hot and cold, radiations, water immersion, etc. The gloves may be worn by patients, care givers, housewives, laboratory and industrial workers, police, etc.
Leukemia, Myeloid, Acute
Disease Progression
Drug Resistance, Multiple
Oncology Nursing
Hematopoietic Stem Cell Transplantation
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Neoplasm Transplantation
Thiotepa
Drug Therapy
Lymphatic Metastasis
Feasibility Studies
Tegafur
Amaryllidaceae Alkaloids
Germinoma
A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)
Drug Evaluation, Preclinical
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Gene Expression Regulation, Neoplastic
P-Glycoprotein
A 170-kDa transmembrane glycoprotein from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS. It serves as an ATP-dependent efflux pump for a variety of chemicals, including many ANTINEOPLASTIC AGENTS. Overexpression of this glycoprotein is associated with multidrug resistance (see DRUG RESISTANCE, MULTIPLE).
Cell Cycle
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Aster Plant
Cell Division
Occupational Exposure
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Neoplasms, Experimental
Mitomycins
Research Design
Immunohistochemistry
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Prodrugs
Quality of Life
Drug Resistance
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Hyperthermia, Induced
Pilot Projects
Epothilones
DNA Damage
Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS.
Vindesine
Multivariate Analysis
Leukemia, Myeloid
Angiogenesis Inhibitors
Enzyme Inhibitors
Amsacrine
Risk Factors
Maintenance Chemotherapy
Cranial Irradiation
Sarcoma
Drug-Related Side Effects and Adverse Reactions
Clinical Trials, Phase III as Topic
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
Platinum
Platinum. A heavy, soft, whitish metal, resembling tin, atomic number 78, atomic weight 195.09, symbol Pt. (From Dorland, 28th ed) It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae".
Medical Secretaries
Inhibitory Concentration 50
Neoplasm, Residual
Predictive Value of Tests
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Molecular Structure
Sulindac
A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.
Actuarial Analysis
The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
Tomography, X-Ray Computed
Lactones
Protective Devices
Tumor Burden
Topotecan
Depsipeptides
Bone Marrow Transplantation
Flow Cytometry
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Bone Marrow
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Drug Delivery Systems
Antibodies, Monoclonal, Murine-Derived
Proportional Hazards Models
Prednisolone
HL-60 Cells
A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)
Lymphoma, Large B-Cell, Diffuse
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
Tumour ablation and hepatic decompensation rates in multi-agent chemoembolization of hepatocellular carcinoma. (1/20433)
Thirty-seven cirrhotic patients with 62 hepatocellular carcinoma (HCC) foci--most Child-Pugh class B or C and/or with large, inoperable tumours--underwent 148 sessions of transcatheter arterial chemoembolization (TACE) using lipiodol, doxorubicin and cisplatin. Treatment efficacy was assessed by serial hepatic arteriography in 34/37 (91.9%) patients and abdominal CT scanning in 3/37 (8.1%) patients. Child-Pugh status was determined prior to each treatment session. Varying degrees of control of tumour neovascularity occurred for a median 390 days (range 90 to > 1680 days) in 33/34 (97.1%) patients in whom progress hepatic arteriography was performed. Ablation of tumour neovascularity occurred in 6/6 (100%), 4/12 (33.3%) and 6/16 (37.5%) patients with HCC diameters < 4 cm, 4-7 cm and > 8 cm, respectively (p < 0.02). Significantly more sessions were required for ablation of larger tumours (p < 0.05). Recurrent HCC was detected in 50% of patients after a median 240 days (range 60-1120 days). Deterioration in Child-Pugh status followed a session of TACE on 19/148 (12.8%) occasions but resulted in unscheduled hospitalization on only 4/148 (2.7%) occasions, the highest incidence (8.3%) in Child-Pugh C patients. Actuarial survival was 27/36 (75.0%) at 6 months, 17/34 (50.0%) at 12 months, 14/34 (41.2%) at 18 months, 9/31 (29.0%) at 24 months and 4/27 (14.8%) at 36 months. Multi-agent TACE with lipiodol, doxorubicin and cisplatin provides a useful anti-tumour effect, even in cirrhotic patients with large HCCs. The incidence of clinically significant deterioration in hepatic function due to ischaemia of non-tumorous liver is acceptably low, even in Child-Pugh C patients. (+info)Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (2/20433)
Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m(-2), 5-fluorouracil 500 mg m(-2), epidoxorubicin 35 mg m(-2), 6S stereoisomer of leucovorin 250 mg m(-2) and glutathione 1.5 mg m(-2), supported by a daily administration of lenograstim at a dose of 5 microg kg(-1). Nineteen patients were men and three were women. Median age was 63 years (range 47-70). At study entry, pain was present in 15 out of 22 patients (68%) with a mean value of Scott-Huskisson scale of 27.6+/-23.8, whereas a weight loss >10% was present in 15 patients. After eight weekly treatments, three partial responses were achieved for a response rate of 13% (95% CI 0-26%), five patients had stable disease and 14 progressed on therapy. Pain was present in 9 out of 22 patients (40%) with a mean value of Scott-Huskisson scale of 12.3+/-18.4. Eight patients (36%) (three partial response and five stable disease) had a positive weight change. Toxicity was mild: WHO grade III or IV toxicity was recorded in terms of anaemia in 7 out of 188 cycles (3.7%), of neutropenia in 9 out of 188 cycles (4.7%) and of thrombocytopenia in 3 out of 188 cycles (1.5%). Median survival of all patients was 6 months. The outcome of this intensive chemotherapy regimen does not support its use in pancreatic cancer. (+info)Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. (3/20433)
Based on an increased frequency of early death (death within the first treatment cycle) in our two latest randomized trials of combination chemotherapy in small-cell lung cancer (SCLC), we wanted to identify patients at risk of early non-toxic death (ENTD) and early toxic death (ETD). Data were stored in a database and logistic regression analyses were performed to identify predictive factors for early death. During the first cycle, 118 out of 937 patients (12.6%) died. In 38 patients (4%), the cause of death was sepsis. Significant risk factors were age, performance status (PS), lactate dehydrogenase (LDH) and treatment with epipodophyllotoxins and platinum in the first cycle (EP). Risk factors for ENTD were age, PS and LDH. Extensive stage had a hazard ratio of 1.9 (P = 0.07). Risk factors for ETD were EP, PS and LDH, whereas age and stage were not. For EP, the hazard ratio was as high as 6.7 (P = 0.0001). We introduced a simple prognostic algorithm including performance status, LDH and age. Using a prognostic algorithm to exclude poor-risk patients from trials, we could minimize early death, improve long-term survival and increase the survival differences between different regimens. We suggest that other groups evaluate our algorithm and exclude poor prognosis patients from trials of dose intensification. (+info)Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. (4/20433)
Dihydropyrimidine dehydrogenase (DPD) is responsible for the breakdown of the widely used antineoplastic agent 5-fluorouracil (5FU), thereby limiting the efficacy of the therapy. To identify patients suffering from a complete or partial DPD deficiency, the activity of DPD is usually determined in peripheral blood mononuclear cells (PBM cells). In this study, we demonstrated that the highest activity of DPD was found in monocytes followed by that of lymphocytes, granulocytes and platelets, whereas no significant activity of DPD could be detected in erythrocytes. The activity of DPD in PBM cells proved to be intermediate compared with the DPD activity observed in monocytes and lymphocytes. The mean percentage of monocytes in the PBM cells obtained from cancer patients proved to be significantly higher than that observed in PBM cells obtained from healthy volunteers. Moreover, a profound positive correlation was observed between the DPD activity of PBM cells and the percentage of monocytes, thus introducing a large inter- and intrapatient variability in the activity of DPD and hindering the detection of patients with a partial DPD deficiency. (+info)Patterns of care and survival for adolescents and young adults with acute leukaemia--a population-based study. (5/20433)
We report a population-based study of patterns of care and survival for people with acute leukaemia diagnosed at age 15-29 years during 1984-94 in regions of England and Wales covered by specialist leukaemia registries. There were 879 patients: 417 with acute lymphoblastic leukaemia (ALL) and 462 with acute myeloid leukaemia (AML). For ALL, actuarial survival rates were 43% at 5 years after diagnosis and 37% at 10 years. Survival improved significantly between 1984-88 and 1989-94 for those aged 15-19 at diagnosis. Patients entered in national clinical trials and those not entered had similar survival rates. Survival rates were similar at teaching and non-teaching hospitals and at hospitals treating different numbers of study patients per year. For AML, survival rates were 42% at 5 years after diagnosis and 39% at 10 years. Survival improved significantly between 1984-88 and 1989-94. Patients entered in the Medical Research Council AML10 trial had a higher survival rate than those who were in the earlier AML9 trial. Survival did not vary with category of hospital. We conclude that survival has improved for adolescents and young adults with acute leukaemia but that there is at present no evidence that centralized treatment results in a survival benefit for patients in this age group. (+info)The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (6/20433)
We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients. (+info)Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. (7/20433)
The effect of an extensive prophylactic antimicrobial regimen was prospectively assessed in 126 patients after high-dose chemotherapy and autologous PBSC. They received ciprofloxacin (500 mg/12 h), acyclovir (200 mg/6 h), and itraconazole (200 mg/12 h) orally until neutrophil recovery. Febrile patients received i.v. imipenem (500 mg/6 h) to which vancomycin and amikacin were added if fever persisted for 2-3 and 5 days, respectively. Amphotericin B lipid complex was further given on day 7 or 8 of fever. Median times for a neutrophil count of >0.5 x 10(9)/l and a platelet count of >20 x 10(9)/l were 9 and 11 days. Severe neutropenia (<0.1 x 10(9)/l) lasted for a median of 5 days in which 72% of febrile episodes and 50% of cases of bacteremia occurred. Gram-positive bacteria were isolated in 30 of 40 episodes of bacteremia, 25 of which were caused by Staphylococcus epidermidis. Clinical foci were the intravascular catheter in 35 cases, respiratory infection in 11, cellulitis in two, anal abscess in one, and neutropenic enterocolitis in one. The high incidence of febrile episodes (94%) and bacteremias (31%) may be due to the lack of efficacy of antimicrobial prophylaxis and the persistence of a 5-day period of severe neutropenia. (+info)Central venous catheter exchange by guidewire for treatment of catheter-related bacteraemia in patients undergoing BMT or intensive chemotherapy. (8/20433)
Current guidelines for the treatment of catheter-related bacteraemia (CRB) advise against central venous catheter (CVC) exchange because of the potential risk of prolonging infection. However, there are no consistent data proving this recommendation. We evaluated prospectively the usefulness of CVC exchange by guidewire for the treatment of CRB in patients undergoing BMT or intensive chemotherapy. CVC exchange was considered when fever and positive blood cultures persisted after 2 days of adequate antimicrobial therapy and no potential source of bacteraemia other than CVC could be identified. The guidewire exchange was preceded and followed by a slow infusion of adequate antimicrobial therapy. Bacteraemia was confirmed as catheter-related by demonstrating concordance between isolates from the tip and blood cultures by pulsed-field electrophoresis of genomic DNA. This procedure was performed in 19 episodes of bacteraemia during a 1-year period. Fourteen episodes (74%) were catheter-related and 71% of these were due to coagulase-negative staphylococci. Guidewire replacement was accomplished uneventfully 4 days after development of sepsis (range 3-6). In all cases, clinical signs of sepsis disappeared in less than 24 h after replacement. Definitive catheter withdrawal was carried out a median of 16 days (range 3-42) after guidewire exchange; in all cases, the tip culture was negative. We conclude that CVC replacement by guidewire under adequate antimicrobial therapy may be a reasonable option for the treatment of CRB when antimicrobial therapy alone has been unsuccessful. (+info)
A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy...
Chemotherapy Regimens - The Purple Society
Chemotherapy regimen - Wikipedia
Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia - Full Text View -...
Multi-agent system - Wikipedia
Increasing dose intensity of chemotherapy reduces the risk of breast cancer recurrence and death - Clinical Trial Service Unit ...
StudyPages - Radiation therapy with/without combination chemotherapy or targeted chemotherapy before surgery in treating...
Chemotherapy
90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic...
Chemo 101 and Sams Chemotherapy Schedule Things about Sam and Leslie
Immuno-oncology in 2019: the rapid evolution continues - PMLiVE
A Phase II Trial of Response-Adapted Therapy of Stage III/IV Hodgkin
Lymphoma Using Early Interim FDG-PET Imaging
Multi-agent Chemotherapy Not Recommended To Replace Chemoradiotherapy in Rectal Cancer - Cancer Therapy Advisor
Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell...
An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy...
Irinotecan and raltitrexed: An active combination in advanced colorectal cancer - Fingerprint
- Italian Ministry of Health
Chemotherapy Induced Neutropenia, Pipeline Review, H1 2015
NewYork-Presbyterian Queens - Chemotherapy Overview
Xelox-2 in untreated patients with advanced colorectal cancer. A Phase II multicenter study of the gruppo oncologico dell...
NCT00936364 Clinical Trial - National Cancer Institute
Systemic chemotherapy treatment options for first-line treatment - Cancer Guidelines Wiki
A Phase Ib Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in...
Chemotherapy doesnt work? Not so fast… (A lesson from history) - Science-Based Medicine
Aflibercept as a second line chemotherapy in metastatic colorectal cancer. One centre experience | OncologyPRO
Additional chemotherapy with doxorubicin marginally improves tumour response but increases side effects with no improvement in...
SEER Training:Chemotherapy
Preventing Chemotherapy Toxicities And Other Issues On Drugs Used In Oncology
Entropy | Free Full-Text | Distributed Consensus of Nonlinear Multi-Agent Systems on State-Controlled Switching Topologies
Roche Extremely Encouraged With TECENTRIQ Cancer Drug
Senescence promotes chemotherapy side effects and cancer relapse | The Buck Institute for Research on Aging
Trends in Recommendations for Myelosuppressive Chemotherapy for the Treatment of Solid Tumors in: Journal of the National...
The sequential administration of XELOX and XELIRI was effective, feasible and manageable for patients with mCRC | OncologyPRO
Alternative Chemotherapy Dosing Strategies Improve Breast Cancer Outcomes
Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non...
High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with...
Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter...
Adjuvant Chemotherapy After Pancreatic Cancer Resection and Neoadjuvant FOLFIRINOX - The ASCO Post
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for...
Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or...
Hyper-CVAD Regimen in Sequential Combination With Blinatumomab as Frontline Therapy for Adults With B-Cell Lineage Acute...
Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcit by Cynthia X Ma, Suresh G. Nair MD et al.
FDA Approves Durvalumab as Part of a First-Line Combination Regimen for Extensive-Stage SCLC - The ASCO Post
Institute of Cancer Research Repository - Perioperative Chemotherapy With or Without Bevacizumab in Patients With Metastatic...
Long-term complete remission with nab-paclitaxel, bevacizumab, and gemcitabine combination therapy in a patient with triple...
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1 -positive metastatic...
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer<...
Seeing the forest through the trees: A systematic review of the safety and efficacy of combination chemotherapies used in the...
Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed...
Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans
Chemotherapy, Cancer Chemotherapy India, Side Effects Chemotherapy
The Efficacy of Chemotherapy for Cancer By Don Benjamin
Adverse effects of bevacizumab and their management in solid tumors<...
Smart Innovation, Systems and Technologies - Agent and Multi-Agent Systems: Technology and Applications - 11th KES...
List of MeSH codes (E02)
... antineoplastic combined chemotherapy protocols MeSH E02.190.044.080 - acupressure MeSH E02.190.044.105 - acupuncture analgesia ... antineoplastic combined chemotherapy protocols MeSH E02.319.162.150 - antibiotic prophylaxis MeSH E02.319.300.253 - delayed- ... antineoplastic combined chemotherapy protocols MeSH E02.319.310.075 - antiretroviral therapy, highly active MeSH E02.319. ...
FLAG (chemotherapy)
The FLAMSA protocol is most often used as an induction part of a reduced-intensity conditioning regimen for patients eligible ... G-CSF is still included, even though the "G" is taken out of the acronym.) Amsacrine is an alkylating antineoplastic agent that ... In this setting, it is often combined with other agents, such as: Cyclophosphamide (FLAMSA-CYC), and/or Busulfan or treosulfan ... FLAG is a chemotherapy regimen used for relapsed and refractory acute myeloid leukemia (AML). The acronym incorporates the ...
Chemotherapy
Springer Protocols. pp. 405-432.. *^ Luqmani YA (2005). "Mechanisms of drug resistance in cancer chemotherapy". Medical ... Combined modality chemotherapy is the use of drugs with other cancer treatments, such as surgery, radiation therapy, or ... Main article: List of antineoplastic agents. There is an extensive list of antineoplastic agents. Several classification ... Intensification chemotherapy is identical to consolidation chemotherapy but a different drug than the induction chemotherapy is ...
Chemotherapy
This type of chemotherapy is used for curative intent. Combined modality chemotherapy is the use of drugs with other cancer ... In the 1970s, antineoplastic (chemotherapy) drugs were identified as hazardous, and the American Society of Health-System ... Generating Inhibitors of P-Glycoprotein: Where to, Now?. Springer Protocols. pp. 405-432. Luqmani YA (2005). "Mechanisms of ... Intensification chemotherapy is identical to consolidation chemotherapy but a different drug than the induction chemotherapy is ...
Cisplatin
Aprepitant combined with ondansetron and dexamethasone has been shown to be better for highly emetogenic chemotherapy than just ... The new protocol that he developed led to a marked increase in disease-free survival rates for patients with medulloblastoma, ... Cisplatin is in the platinum-based antineoplastic family of medications. It works in part by binding to DNA and inhibiting its ... Cisplatin is a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, ...
Silver nanoparticle
See also: Antineoplastic resistance. A major cause for the ineffectiveness of current chemotherapy treatments is multiple drug ... Synthetic protocols for silver nanoparticle production can be modified to produce silver nanoparticles with non-spherical ... second approach is to attach a chemotherapeutic drug directly to the functionalized surface of the silver nanoparticle combined ... Chemotherapy[edit]. The introduction of nanotechnology into medicine is expected to advance diagnostic cancer imaging and the ...
Treatment of lung cancer
The chemotherapy used was Cisplatin or Carboplatin, combined with Gemcitabine for patient with squamous cell NSCLC, or ... with cisplatin or carboplatin as the backbone of all the chemotherapy treatments protocols. Pemetrexed is provided with ... and approved pembrolizumab in combination with pemetrexed and platinum-based antineoplastic (carboplatin or cisplatin) as first ... chemotherapy plus atezolizumab or chemotherapy plus Bevacizumab and atezolizumab. The chemotherapy used was Carboplatin, and ...
Thymidine kinase
Helgstrand E, Oberg B (1980). "Enzymatic targets in virus chemotherapy". Virus Chemotherapy. Antibiotics and Chemotherapy. 27. ... This may also be combined with radioactivity to achieve apoptosis of malignant cells. Some antiviral drugs, such as acyclovir ( ... 2015). "Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2 ... Cold Spring Harbor Protocols. 2016 (2): pdb.prot085118. doi:10.1101/pdb.prot085118. PMID 26832684. Sun R, Eriksson S, Wang L ( ...
Drug discovery
"The purine path to chemotherapy. Nobel Lecture 1988".. *^ Black J. "Drugs from emasculated hormones: the principles of synoptic ... Some descriptors such as ligand efficiency[23] (LE) and lipophilic efficiency[24][25] (LiPE) combine such parameters to assess ... For certain therapy areas, such as antimicrobials, antineoplastics, antihypertensive and anti-inflammatory drugs, the numbers ... agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis". Bioorganic & Medicinal Chemistry Letters ...
Hepatocellular carcinoma
The combined high prevalence of rates of aflatoxin and hepatitis B in settings such as China and West Africa has led to ... Mipsagargin (G-202), has orphan drug designation as a treatment during chemotherapy for HCC. It is a thapsigargin-based prodrug ... Controversy remains as to the most effective screening protocols. For example, while some data support decreased mortality ... "Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells". Biochemical ...
Analgesic
Refractory chemotherapy-induced nausea and vomiting; anorexia; neuropathic pain.. Dizziness, euphoria, paranoia, somnolence, ... Smith, Howard S.; Raffa, Robert B.; Pergolizzi, Joseph V.; Taylor, Robert; Tallarida, Ronald J. (2014-07-01). "Combining opioid ... "Should New Zealand continue signing up to the Pethidine Protocol?" (PDF). The New Zealand Medical Journal. 119 (1230): U1875. ...
Analgesic
Refractory chemotherapy-induced nausea and vomiting; anorexia; neuropathic pain.. Dizziness, euphoria, paranoia, somnolence, ... Smith, Howard S.; Raffa, Robert B.; Pergolizzi, Joseph V.; Taylor, Robert; Tallarida, Ronald J. (2014-07-01). "Combining opioid ... "Should New Zealand continue signing up to the Pethidine Protocol?" (PDF). The New Zealand Medical Journal. 119 (1230): U1875. ...
GENERIC 3204009-Antineoplastic+Combined+Chemotherapy+Protocols
Search of: nabilone OR cesamet AND Antiemetics - List Results - ClinicalTrials.gov
Antineoplastic Combined Chemotherapy Protocols. *Drug: Cesamet™ (nabilone). Interventional. Phase 4. *NEMA Research, Inc. ... A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting. *Nausea and ... Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy. *Peripheral ... To demonstrate incremental improvement with Cesamet in control of chemotherapy induced nausea and vomiting in patients who have ...
Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer - Full Text View -...
Antineoplastic Combined Chemotherapy Protocols. Paclitaxel. Cisplatin. Additional relevant MeSH terms: Lung Neoplasms. ... Antineoplastic Agents, Phytogenic. Antineoplastic Agents. Tubulin Modulators. Antimitotic Agents. Mitosis Modulators. Molecular ... Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer. The safety and ... Effect of Chemotherapy With Paclitaxel and Cisplatin on Development Dysgeusia in Non-small Cell Lung Cancer Patients. ...
Phase II study of sorafenib in co... preview & related info | Mendeley
PURPOSE: The combination of sorafenib with chemotherapy is well-tolerated and is associated with encouraging response rates in ... Antineoplastic Combined Chemotherapy Protocols. *Antineoplastic Combined Chemotherapy Protocols: th. *Benzenesulfonates. * ... A phase II study was conducted to determine the efficacy and toxicity of combined sorafenib, docetaxel, and cisplatin in ... PURPOSE: The combination of sorafenib with chemotherapy is well-tolerated and is associated with encouraging response rates in ...
Perspectives in the treatment of pancreatic adenocarcinoma
Antineoplastic Combined Chemotherapy Protocols / adverse effects * Antineoplastic Combined Chemotherapy Protocols / therapeutic ... However, recently, a regimen combining fluorouracil, irinotecan, oxaliplatin, and leucovorin (FOLFIRINOX) and another combining ... In addition, PDAC cells promote a dense functional stroma that facilitates tumor resistance to chemotherapy and radiation. ... Keywords: Adoptive T cell therapy; Antibody therapy; Biomarkers; Chemotherapy; Immune surveillance; Immunotherapy; Inhibitors; ...
Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment...
This study has identified pathway specific prognostic biomarkers possibly underlying a differential chemotherapy response in ... Antineoplastic Combined Chemotherapy Protocols / therapeutic use* * Carcinoma, Ovarian Epithelial * Cluster Analysis * Drug ... Background: Resistance to platinum-based chemotherapy remains a major impediment in the treatment of serous epithelial ovarian ... Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment ...
Estudo de fase I/II de Erlotinib (OZI-774) combinado com radioterapia e cisplatina...
Antineoplastic agents. Antineoplastic combined chemotherapy protocols. Carcinoma squamous cell/drug therapy. Carcinoma squamous ... Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell ... and possibly has a synergistic interaction with chemotherapy and radiotherapy. We investigated the safety and efficacy of ...
Antibody responses to Hepatitis B and measles-mumps-rubella vaccines in children who received chemotherapy for acute...
Keywords : Leukemia, lymphoid; Antineoplastic combined chemotherapy protocols; Immunization; Viral vaccines; Child. · text in ... RESULTS: After chemotherapy, 75.9%, 67.9%, 59.3% and 51.7% of the patients showed low antibody titers that would be unlikely to ... OBJECTIVE: To evaluate viral vaccine antibody levels in children with acute lymphoblastic leukemia after chemotherapy and after ... Antibody responses to Hepatitis B and measles-mumps-rubella vaccines in children who received chemotherapy for acute ...
Clinical Index of Stable Febrile Neutropenia - Trip Database
Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy / ... Combine searches by placing the search numbers in the top search box and pressing the search button.. An example search might ... 17.T reatment with high-dose chemotherapy outside II 314, 315 6.2 of clinical trials is not recommended. 18.Women should be ... Received steroid therapy with in 7 days prior to 1st dose of study drug for anti-neoplastic intent. Received any anti (...) and ...
A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
Insulin receptor substrate 1 expression enhances the sensitivity of 32D cells to chemotherapy-induced cell death.
Antineoplastic Combined Chemotherapy Protocols / pharmacology*. Cell Death / drug effects. Cells, Cultured. Dose-Response ... The role of IRS1 and IRS2 in controlling cell responses to chemotherapy is unknown. To determine the role of IRS1 and IRS2 in ... We found that expression of IRS1, in contrast to IRS2, enhanced the sensitivity of 32D cells to chemotherapy-induced apoptosis ... Decreasing Annexin A2 levels reduced 32D-IRS1 cell sensitivity to chemotherapy. These results suggest IRS1 enhances sensitivity ...
Brazilian experience using high dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for...
Antineoplastic Combined Chemotherapy Protocols [administration & dosage]; Cyclophosphamide [administration & dosage]; ... DUARTE, Bruno Kosa Lino et al. Brazilian experience using high dose sequential chemotherapy followed by autologous ... Chemotherapy consisted of the sequential administration of high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte-colony ... OBJECTIVE: To evaluate the use of high-dose sequential chemotherapy in a Brazilian population. METHODS: High-dose ...
Clinical recommendations for diagnosis, treatment and monitoring of patients with bladder cancer
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS - therapeutic use; CISPLATIN - therapeutic use; COMBINED MODALITY THERAPY; ... Adjuvant sandwich chemotherapy plus radiotherapy vs adjuvant chemotherapy alone for locally advanced bladder cancer after ... Combined Positive Score) mora biti ≥ 10. Imunoterapija se može primijeniti bez obzira na razinu izraženosti PD-L1 u bolesnika ... Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in ...
Program Members > Yale Cancer Center | Yale School of...
Program Members
Sadhna Raju Vora, M.D. | Harvard Catalyst Profiles | Harvard Catalyst
Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
Antineoplastic Combined Chemotherapy Protocols. *Breast Neoplasms. *Neoplasms. *Lung Neoplasms. *Ovarian Neoplasms. *Prostatic ... Chemotherapy, radiation therapy, immunotherapy, or systemic biologic. - anticancer therapy within 21 days before beginning ... progressed during or after one or more chemotherapy regimens; Metastatic breast. cancer; Hormone-refractory prostate cancer; ...
Dan-Arin Silasi, MD | Yale School of Medicine
Antineoplastic Combined Chemotherapy Protocols. *Pelvic Exenteration. *Pelvic Neoplasms. *Chemotherapy, Cancer, Regional ... In Combination With And/or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer ... or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy ... Versus Investigators Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, ...
AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor
Plus it
Antineoplastic combined chemotherapy protocols. With the important exception of the E4599 trial of bevacizumab in conjunction ... Trials combining cetuximab with chemotherapy have shown a trend to increased response rate and prolonged progression-free ... ATLAS is a phase III trial of bevacizumab with chemotherapy followed by erlotinib after chemotherapy is completed that will ... that combined novel agents with standard chemotherapy have produced disappointing or equivocal results. Many agents identified ...
CLINICAL GUIDELINES FOR DIAGNOSIS, TREATMENT AND MONITORING PATIENTS WITH COLORECTAL CANCER
Antineoplastic combined chemotherapy protocols; Chemotherapy, adjuvant; Combined modality therapy; Neoplasm staging; Neoplasm ... Irinotecan combined with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised ... Jalil O, Claydon L, Arulampalam T. Review of neoadjuvant chemotherapy alone in locally advance rectal cancer. J Gastrointest ... American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22 ...
Academic Programs Faculty - Last Initial L - Wake Forest School of Medicine
Lymphoma, Non-Hodgkin; Antineoplastic Combined Chemotherapy Protocols; Hemangiopericytoma; Meningioma; Antiretroviral Therapy, ... Peritoneal Neoplasms; Hyperthermia, Induced; Chemotherapy, Cancer, Regional Perfusion; Adenocarcinoma; Antineoplastic Combined ... Carcinoma, Lobular; Biopsy; Antineoplastic Agents; Breast Neoplasms; Chemoprevention Academic: 336-716-4316. Department: 336- ... Brain Neoplasms; Glioma; Glioblastoma; Central Nervous System Neoplasms; Antineoplastic Agents Academic: 336-716-9527. ...
Marcel B Bally's Research on integrin-linked kinase
| CureHunter
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia...
Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer
Adult; Aged; Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Bayes Theorem; Biomarkers, Tumor / ... Genomic test-directed chemotherapy (using the Oncotype DX 21-gene assay) was compared with chemotherapy alone (standard care) ... The study objective was to assess the cost-effectiveness of genomic test-directed chemotherapy versus chemotherapy alone for ... This study assessed the cost-effectiveness of genomic test-directed chemotherapy versus chemotherapy alone in patients with ...
Kaplan-Meier's estimate of overall survival and event-f | Open-i
Antineoplastic Combined Chemotherapy Protocols/therapeutic use. *Child. *Cohort Studies. *Cyclin D1/metabolism ... The combined TP53/MIPI show significant (P = 0·006) separation between low and intermediate risk groups in relation to (G) OS ... The combined TP53/MIPI show significant (P = 0·006) separation between low and intermediate risk groups in relation to (G) OS ... The combined SOX11/MIPI improves separation between low and intermediate risk groups (although, P , 0·05) in relation to (E) OS ...
The miR-21-mediated program is modified by 5-fluorourac | Open-i
Antineoplastic Combined Chemotherapy Protocols/therapeutic use. *Blotting, Western. *Cell Line, Tumor. *Cell Proliferation/drug ... Taken together, our findings demonstrate that microRNA-21 is a chemotherapy responsive microRNA and can serve as a prognostic ... Taken together, our findings demonstrate that microRNA-21 is a chemotherapy responsive microRNA and can serve as a prognostic ... However, the utility of specific microRNAs in predicting the clinical benefit of chemotherapy has not been well-established. ...
ʿ?? 2018???? ?? - ?????? IJ ??
Portal Regional da BVS
Neoplasms, Medical Oncology, Radiotherapy, Antineoplastic Protocols, Antineoplastic Combined Chemotherapy Protocols, ... Antineoplastic Protocols, Antineoplastic Combined Chemotherapy Protocols, Precancerous Conditions, Cancer Symptoms, Feeding and ... Antineoplastic Protocols, Antineoplastic Combined Chemotherapy Protocols, Precancerous Conditions, Cancer Symptoms, Feeding and ... Antineoplastic Protocols, Antineoplastic Combined Chemotherapy Protocols, Precancerous Conditions, Genetics, Genes, Neoplasm, ...
CarcinomaRadiotherapyAdultPlatinum-based chemotherapyTumorCyclophosphamideApoptosisTherapeuticCombination chemotherapyCarboplatinSurvivalRegimensAdenocarcinomaBiomarkersResponse to chemotherapyPatientsTherapyDocetaxelCancerToxicityAcute lymphoblAntigensAutologousAgentsEfficacyMETHODSNeoadjuvant chemotherapyCourses of chemotherapyRegimenPrognosticTreatmentVersusNeutropenia
Carcinoma5
- Purpose: Erlotinib, an oral tyrosine-kinase inhibitor, is active against squamous cell carcinoma of the head and neck (HNSCC) and possibly has a synergistic interaction with chemotherapy and radiotherapy. (usp.br)
- Here, we investigated the correlation between microRNA-21 expression and hepatic arterial infusion chemotherapy with 5-fluorouracil and pirarubicin (HAIC) for hepatocellular carcinoma (HCC). (nih.gov)
- Conclusion: VEGF expression alone was an important marker of good response to neoadjuvant chemotherapy in patients with advanced carcinoma of the cervix. (bvsalud.org)
- METHODS: We searched for English-language publications through Pubmed using a combination of the following key words: endometrial carcinoma, clear cell carcinoma, recurrence, prognosis, adjuvant therapy, radiation treatment and chemotherapy. (henryford.com)
- Sixty-two patients with metastatic colorectal carcinoma involving the liver were treated by hepatic intra-arterial chemotherapy using an implantable infusion pump. (emmes.com)
Radiotherapy6
- Which alters the feeding of cancer patients, contributing to the anorexia, weight loss and malnutrition, which leads to a prognostic impact in a lower patient response to chemotherapy, radiotherapy and surgical treatment as well as increased toxic effects, impacting treatment discontinuation and therefore, morbidity and survival of patients. (clinicaltrials.gov)
- Treatment options in metastatic disease range from cisplatin-based chemotherapy, immunotherapy, palliative radiotherapy and finally supportive care. (srce.hr)
- Concurrent treatment with any other anticancer therapy, including chemotherapy, immunotherapy, radiotherapy (excluding radiotherapy with palliative intent on non-target lesions), targeted therapy, gene therapy, or patients planning to receive these treatments during the study. (knowcancer.com)
- The treatment outcomes of this disease have improved significantly in recent years due to the improvement of diagnostic methods (pathohistology, radiology, nuclear medicine), screening and treatment improvements: surgical and oncological (chemotherapy, immunotherapy, radiotherapy). (srce.hr)
- Weekly cisplatin (30 mg/m) and oral vinorelbine (30 mg/m) were combined with standard thoracic radiotherapy (66 Gy, 33 fractions) for 6.5 weeks. (cepia.team)
- The therapeutic gain of radiotherapy may be further improved with the addition of systemic chemotherapy. (henryford.com)
Adult2
- DISCUSSION: This trial is the first in the world to test a remote monitoring/management intervention for adult haematological cancer patients receiving chemotherapy. (strath.ac.uk)
- Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. (gu.se)
Platinum-based chemotherapy4
- Resistance to platinum-based chemotherapy remains a major impediment in the treatment of serous epithelial ovarian cancer. (nih.gov)
- All 28 patients had advanced stage, high-grade serous ovarian cancer, and were treated with standard platinum-based chemotherapy. (nih.gov)
- Conversely, in patients with MIBC radical cystectomy remains the corne stone of the treatment, optimally in conjunction with neoadjuvant platinum-based chemotherapy in cisplatin-eligible patients. (srce.hr)
- The role of platinum-based chemotherapy as an adjuvant therapy for early stage NSCLC has been unequivocally established. (aacrjournals.org)
Tumor5
- In addition, PDAC cells promote a dense functional stroma that facilitates tumor resistance to chemotherapy and radiation. (nih.gov)
- BACKGROUND: Combined treatment approaches targeting tumor cells as well as stromal cells may control chemorefractory malignancies. (uni-regensburg.de)
- The children were followed up to 6 months after chemotherapy, and the two groups were compared in terms of visual acuity and tumor size before and after chemotherapy and adverse reactions during chemotherapy. (bvsalud.org)
- [email protected]#The combined chemotherapy group had a significantly higher proportion of children achieving tumor regression than the conventional chemotherapy group (P0.05). (bvsalud.org)
- Combined with castration, ganetespib displayed deeper PDX tumor regressions and delayed castration resistance relative to either monotherapy. (nih.gov)
Cyclophosphamide4
- Chemotherapy consisted of the sequential administration of high-dose cyclophosphamide (4 or 7 g/m 2 ) and granulocyte-colony stimulating factor (300 µg/day), followed by peripheral blood progenitor cell harvesting, administration of etoposide (2g/m 2 ) and methotrexate (8 g/m 2 only for Hodgkin's lymphoma) and autologous hematopoietic stem cell transplantation. (scielo.br)
- In conclusion, purine analogs, particularly combined with cyclophosphamide, significantly improve progression free survival but not survival. (ox.ac.uk)
- Amsacrine is an alkylating antineoplastic agent that is highly active toward AML, unlike more conventional alkylators like cyclophosphamide. (wikipedia.org)
- In this setting, it is often combined with other agents, such as: Cyclophosphamide (FLAMSA-CYC), and/or Busulfan or treosulfan (FLAMSA-BU or FLAMSA-TREO), and/or Melphalan (FLAMSA-MEL), and/or Total body irradiation, given shortly after the end of FLAMSA to prepare the patient for transplant. (wikipedia.org)
Apoptosis1
- We found that expression of IRS1, in contrast to IRS2, enhanced the sensitivity of 32D cells to chemotherapy-induced apoptosis. (biomedsearch.com)
Therapeutic1
- However, recently, a regimen combining fluorouracil, irinotecan, oxaliplatin, and leucovorin (FOLFIRINOX) and another combining albumin-bound paclitaxel with gemcitabine have shown clear therapeutic advantage in advanced PDAC, with survival outcomes of 11.3 and 8.5 mo on phase III trials, respectively, over single-agent gemcitabine. (nih.gov)
Combination chemotherapy4
- With the important exception of the E4599 trial of bevacizumab in conjunction with combination chemotherapy, recent clinical trials in non-small cell lung cancer (NSCLC) that combined novel agents with standard chemotherapy have produced disappointing or equivocal results. (aacrjournals.org)
- 89% of these patients received combination chemotherapy. (umassmed.edu)
- CONCLUSION: Standard (non-antimetabolite) combination chemotherapy administered past the first trimester, as early as 13 weeks gestation, was associated with few complications and expected maternal survival with lymphoma occurring during pregnancy. (umassmed.edu)
- Between 1983 and 1990, 128 patients with limited disease small cell lung cancer (SCLC) received consolidative thoracic irradiation after reaching a complete (CR) or partial response (PR) to combination chemotherapy. (vumc.nl)
Carboplatin3
- Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies. (medscimonit.com)
- BACKGROUND: High-dose chemotherapy with tandem or triple carboplatin and etoposide course is currently the first curative choice for relapsing GCT. (unimi.it)
- According to whether bevacizumab was used, they were divided into conventional chemotherapy (carboplatin, vincristine and etoposide) group with 12 children and combined chemotherapy (bevacizumab, carboplatin, vincristine and etoposide) group with 18 children. (bvsalud.org)
Survival5
- The study cohort comprised 28 patients divided into two groups based on their varying sensitivity to first-line chemotherapy using progression free survival (PFS) as a surrogate of response. (nih.gov)
- Patients treated in CR1 with SCT, autologous SCT or chemotherapy had a survival of 18 +/- 9, 5 +/- 5 and 41 +/- 5%, respectively. (diva-portal.org)
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. (lenus.ie)
- PURPOSE: The addition of bevacizumab to cytotoxic chemotherapy has demonstrated a progression-free survival (PFS) benefit in the first-line and second-line treatment of advanced or metastatic breast cancer (MBC). (ox.ac.uk)
- however, two long-term pilot studies suggest that IL-2 and IFNbeta, when used appropriately can have a positive effect on clinical benefit and overall survival of patients with minimal residual disease after chemotherapy or with disseminated disease controlled by conventional endocrine therapy. (nih.gov)
Regimens2
- BACKGROUND: Moderate differences in efficacy between adjuvant chemotherapy regimens for breast cancer are plausible, and could affect treatment choices. (ox.ac.uk)
- CONCLUSION: As adjuvant chemotherapy for stage III colon cancer, mFOLFOX6/XELOX regimens are acceptable. (springernature.com)
Adenocarcinoma3
- A phase II study was conducted to determine the efficacy and toxicity of combined sorafenib, docetaxel, and cisplatin in patients with metastatic or advanced adenocarcinoma of stomach or gastroesophageal junction (GEJ). (mendeley.com)
- PATIENTS AND METHODS: Forty-four chemotherapy-naïve patients with Eastern Cooperative Oncology Group performance status 0 or 1, of whom 80% had metastatic disease and two thirds had poorly differentiated gastric or GEJ adenocarcinoma, were enrolled. (mendeley.com)
- Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma]. (lenus.ie)
Biomarkers2
- The objective of this study was to use gene expression profiling to delineate major deregulated pathways and biomarkers associated with the development of intrinsic chemotherapy resistance upon exposure to standard first-line therapy for ovarian cancer. (nih.gov)
- This study has identified pathway specific prognostic biomarkers possibly underlying a differential chemotherapy response in patients undergoing standard platinum-based treatment of serous epithelial ovarian cancer. (nih.gov)
Response to chemotherapy2
- Results: eighteen patients (45%) had good response to chemotherapy, and 22 (55%), poor response. (bvsalud.org)
- When analyzed separately for response to chemotherapy, only the positive expression of VEGF was associated with good clinical response (p=0.0157). (bvsalud.org)
Patients26
- The objective of this study is to describe the threshold of perception and recognition of basic tastes in patients with NSCLC before treatment with platin and paclitaxel-based chemotherapy and after the second cycle, and analyze the effect in the developement of dysgeusia, as well as the association between these and the nutritional status and quality of life. (clinicaltrials.gov)
- After chemotherapy, 75.9%, 67.9%, 59.3% and 51.7% of the patients showed low antibody titers that would be unlikely to protect against exposure to measles, rubella, hepatitis B and mumps, respectively. (scielo.br)
- This study assessed the cost-effectiveness of genomic test-directed chemotherapy versus chemotherapy alone in patients with early-stage breast cancer. (york.ac.uk)
- The study objective was to assess the cost-effectiveness of genomic test-directed chemotherapy versus chemotherapy alone for patients with oestrogen receptor-positive, lymph node-positive early-stage breast cancer. (york.ac.uk)
- patients were allocated a to standard care group where they all received chemotherapy or to a test where patients were allocated to high-risk or low risk recurrence groups. (york.ac.uk)
- For patients who received Oncotype DX-directed chemotherapy, the QALYs gained were 10.32 and the cost per patient was £23,130. (york.ac.uk)
- For patients who received standard care (chemotherapy alone), the QALYs gained were 10.16 and the cost per patient was £22,270. (york.ac.uk)
- Taken together, our findings demonstrate that microRNA-21 is a chemotherapy responsive microRNA and can serve as a prognostic biomarker for HCC patients undergoing HAIC. (nih.gov)
- This paper presents the protocol for a Phase 3 multi-site randomised controlled trial evaluating a novel nurse-led Telehealth intervention for remote monitoring/management of chemotherapy side-effects in Australian haematological cancer patients. (strath.ac.uk)
- Patients will be randomised 1:1 to either the control or intervention arm with stratification by diagnosis, chemotherapy toxicity (high versus low), receipt of previous chemotherapy and hospital. (strath.ac.uk)
- Intervention patients will be provided with a computer tablet and software prompting twice-daily completion of physical/emotional scales for up to four chemotherapy cycles. (strath.ac.uk)
- METHODS: A Phase II trial was initiated to analyze the activity of a continuously administered molecularly targeted treatment regimen (daily pioglitazone [45 mg administered orally] and rofecoxib [25 mg administered orally]) combined with sequentially added angiostatic chemotherapy for patients with previously treated metastatic melanoma (n = 19) or soft tissue sarcoma (n = 21). (uni-regensburg.de)
- CONCLUSIONS: To our knowledge, the current study is the first to demonstrate that a novel, completely orally administered combined biomodulator/metronomic chemotherapy regimen may be active and well tolerated in patients with chemorefractory malignancies. (uni-regensburg.de)
- Of 463 patients enrolled in the international ALCL99 trial, 36 (8%) had stage I disease and were treated with a prephase chemotherapy, followed by either 3 chemotherapy courses in case of initial complete resection (6 patients) or otherwise by 6 courses of chemotherapy (30 patients). (gu.se)
- RESULTS: Ninety-four per cent of patients received at least three courses of chemotherapy. (eur.nl)
- The phase III CONFIRM clinical trials demonstrated that metastatic colorectal cancer patients with elevated serum lactate dehydrogenase (LDH) had improved outcome when the vascular endothelial growth factor receptor (VEGFR) inhibitor PTK/ZK (Vatalanib) was added to FOLFOX4 chemotherapy. (qub.ac.uk)
- Lenz, H-J. / Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib) . (qub.ac.uk)
- Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit. (wakehealth.edu)
- Temsirolimus activity was preserved in patients with prior adjuvant chemotherapy. (umassmed.edu)
- All patients underwent neoadjuvant chemotherapy and evaluation for clinical response and expression of VEGF. (bvsalud.org)
- PURPOSE: Adjuvant chemotherapy with oxaliplatin combined with a fluoropyrimidine derivative is widely accepted as standard therapy for patients with stage III colon cancer, since few clinical data are available for Japanese patients. (springernature.com)
- This prospective, multicenter, phase II study was undertaken to evaluate the ability of a comprehensive geriatric assessment (CGA) to select the elderly La-NSCLC patients who potentially may benefit from concurrent radio-chemotherapy. (cepia.team)
- Twenty-six (49%) of the 53 patients developed hepatitis during infusion chemotherapy, which resolved after temporary cessation of the chemotherapy. (emmes.com)
- Eleven patients had evidence of peptic ulceration by endoscopic examination during the infusion chemotherapy. (emmes.com)
- PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial. (cepia.team)
- The FLAMSA protocol is most often used as an induction part of a reduced-intensity conditioning regimen for patients eligible to undergo an allogeneic stem cell transplant. (wikipedia.org)
Therapy4
- Angiostatic chemotherapy consisted of trofosfamide (50 mg) administered orally 3 times daily beginning on the 15th day after the start of molecularly targeted therapy. (uni-regensburg.de)
- INTERPRETATION: 10-year gains from a one-third breast cancer mortality reduction depend on absolute risks without chemotherapy (which, for oestrogen-receptor-positive disease, are the risks remaining with appropriate endocrine therapy). (ox.ac.uk)
- Evidence for combined radiation therapy with systemic chemotherapy in women with advanced stage UCCC has remained debatable. (henryford.com)
- In vitro combined effect of Doxorubicin and sulfonated zinc Phthalocyanine-mediated photodynamic therapy on MCF-7 breast cancer cells. (nextbio.com)
Docetaxel2
- The aim of the current study was to retrospectively explore the prognosis and predictive values of TP53 somatic mutations in the BIG 02-98 randomized phase III trial in which women with node-positive breast cancer were treated with adjuvant doxorubicin-based chemotherapy with or without docetaxel. (strath.ac.uk)
- This trial aims to determine if the MEK inhibitor selumetinib (AZD6244) increases the efficacy of docetaxel, a standard of care chemotherapy. (kobv.de)
Cancer2
- Additional studies of sorafenib with chemotherapy are warranted in gastric cancer. (mendeley.com)
- The direct costs included were treatment of recurrences and distant recurrences, terminal care, cancer treatment, out-patient care, genomic testing with Oncotype DX test, and chemotherapy-related toxicities treatment (including gut perforation, bleeding, thrombosis, allergic reactions and hypertension). (york.ac.uk)
Toxicity1
- However, this treatment modality is fraught with difficulties associated with toxicity and also the emergence of chemotherapy resistance is a considerable problem. (surrey.ac.uk)
Acute lymphobl1
- To evaluate viral vaccine antibody levels in children with acute lymphoblastic leukemia after chemotherapy and after vaccine booster doses. (scielo.br)
Antigens1
- Antibody levels against hepatitis B, rubella, measles and mumps vaccine antigens were evaluated in 33 children after completing chemotherapy (before and after vaccine booster doses) and the results were compared to the data of 33 healthy children matched for gender, age and social class. (scielo.br)
Autologous1
- In case of relapse of aggressive lymphoma or if not obtaining CR, high dose chemotherapy with autologous stem cell support (HDT) is standard treatment. (diva-portal.org)
Agents1
- To determine the role of IRS1 and IRS2 in the sensitivity of cells to chemotherapy, we treated 32D cells lacking or expressing IRS proteins with various concentrations of chemotherapeutic agents. (biomedsearch.com)
Efficacy1
- The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. (lenus.ie)
METHODS1
- [email protected]#A retrospective analysis was performed for the clinical data of 30 children with OPG who underwent chemotherapy. (bvsalud.org)
Neoadjuvant chemotherapy1
- ABSTRACT Objective: to analyze the expression of Vascular Endothelial Growth Factor (VEGF), its receptor (VEGFR-2), age and histological type of advanced cervical carcinomas with respect to the clinical response to neoadjuvant chemotherapy. (bvsalud.org)
Courses of chemotherapy1
- RESULTS: Following 236 courses of chemotherapy, 112 positive blood cultures were registered. (forskningsdatabasen.dk)
Regimen1
- FLAG is a chemotherapy regimen used for relapsed and refractory acute myeloid leukemia (AML). (wikipedia.org)
Prognostic1
- Furthermore, we explored the possibility of creating an improved prognostic tool by combining the MIPI with information on molecular markers.SOX11 was shown to significantly add prognostic information to the MIPI, but in multivariate analysis TP53 was the only significant independent molecular marker.Based on these findings, we propose that TP53 and SOX11 should routinely be assessed and that a combined TP53/MIPI score may be used to guide treatment decisions. (nih.gov)
Treatment4
- In the current study, the authors sought to test one such combined approach in the treatment of chemorefractory melanoma and soft tissue sarcoma. (uni-regensburg.de)
- Chemotherapy remains the mainstay in the treatment and management of many cancers. (surrey.ac.uk)
- The high rate of VGS seemed independent of high-dose cytarabine but was more likely caused by the intensive chemotherapy treatment leading to severe mucositis and neutropenia. (forskningsdatabasen.dk)
- Continuation of the planned cycle rate of protocol treatment was 69.9% in the mFOLFOX6 group and 68.4% in the XELOX group. (springernature.com)
Versus1
- and polychemotherapy versus no chemotherapy (n=32,000). (ox.ac.uk)
Neutropenia1
- This condition could be more often recognised by careful follow-up of liver function test, C-reactive protein level, ultrasonography, CT and MRI after recovery from chemotherapy-induced neutropenia. (lu.se)